Wolverine Trading
CUE icon

Wolverine Trading’s Cue Biopharma CUE Stock Holding History

Wolverine Trading’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-371
Closed -$25.6K – 4597
2023
Q3 		$25.6K Buy
+371
New +$36.2K ﹤0.01% 4294
2022
Q2 		– Sell
-336
Closed -$47K – 4689
2022
Q1 		$47K Buy
+336
New +$71.2K ﹤0.01% 5090

Other funds holding CUE

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Wolverine Trading's CUE Position: Q4 2023 in Review

Wolverine Trading sold out of Cue Biopharma (CUE) in Q4 2023, closing a stake of 371 shares — an estimated $25.6K sold.

Wolverine Trading first reported a position in CUE in Q1 2022 and held it in 2 quarters. The position peaked at $47K in Q1 2022. 80 funds tracked by Wall St. Rank hold CUE as of Q4 2023.

  • Wolverine Trading reported no remaining Cue Biopharma position as of Q4 2023 after selling out during the quarter.
  • Wolverine Trading sold 371 Cue Biopharma shares in Q4 2023, an estimated $25.6K.
  • Wolverine Trading first reported a position in Cue Biopharma in Q1 2022 and held it in 2 quarters.
  • Wolverine Trading's Cue Biopharma position peaked at $47K in Q1 2022.
  • 80 funds tracked by Wall St. Rank held Cue Biopharma as of Q4 2023.

Based on Wolverine Trading's 13F filing for Q4 2023, filed 14 Feb 2024.